Safety of high-dose daptomycin in obese patients: a multicentric retrospective study.
| dc.rights.license | open | en_US |
| dc.contributor.author | DIAS MEIRELES, Vasco | |
| dc.contributor.author | AIRAUD, Clémentine | |
| dc.contributor.author | DEMAY, Elouan | |
| hal.structure.identifier | Microbiologie Fondamentale et Pathogénicité [MFP] | |
| dc.contributor.author | CAZANAVE, Charles | |
| hal.structure.identifier | Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases | |
| dc.contributor.author | XUEREB, Fabien | |
| dc.contributor.author | LAZARO, Pauline | |
| dc.contributor.author | BACLE, Astrid | |
| hal.structure.identifier | Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases | |
| dc.contributor.author | LAHOUATI, Marin | |
| dc.date.accessioned | 2025-03-04T12:54:55Z | |
| dc.date.available | 2025-03-04T12:54:55Z | |
| dc.date.issued | 2025-02-24 | |
| dc.identifier.issn | 1435-4373 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/205341 | |
| dc.description.abstractEn | Obese patients treated with daptomycin at 4 mg/kg have a 30% increased drug exposure, potentially raising the risk of adverse events (AEs) like rhabdomyolysis. Given limited data on the safety of higher doses (10 mg/kg) in this population, this study aimed to assess the safety of high-dose daptomycin in obese patients and to identify potential AEs risk factors. This multicenter, retrospective observational study was conducted from June 2021 to May 2022 using medical records. Patients with a BMI > 30 kg/m were classified as obese. AEs assessed included: CK elevation (> 5x upper limit of normal), severe elevation (> 10x upper limit), eosinophilic pneumonia, and elevated liver enzymes. Both univariate and multivariate analyses were conducted. A total of 1 303 patients were included: 970 non-obese and 333 Ob patients. These patients received an average daptomycin dose of 9.9 mg/kg based on actual body weight for an average treatment duration of 8.27 days. One-third of the patients had CK monitoring. AEs rates were 3.5% for the n-Ob group vs. 8.7% in the Ob group (p < 0.01). Ob patients had significantly higher CK levels (n-Ob, 9.5%; Ob, 20.3%; p = 0.001), and severe elevation (n-Ob, 5.2%; Ob, 10.9%; p = 0.03). Factors increasing AE risk included obesity, concomitant prescriptions of drugs with risk of rhabdomyolysis, eGFR 30-60 mL/min, and daptomycin duration (OR = 2.42; 4.34; 2.03 and 1.05, respectively, p < 0.001). On the opposite, consultation with an infectious disease specialist reduced risk (OR = 0.52, p = 0.024). This study highlights that obese patient has a significantly increased risk of AEs with high dose of daptomycin compared to non-obese patients. Adjusted body weight dosing may be considered to reduce AEs risk. | |
| dc.language.iso | EN | en_US |
| dc.title.en | Safety of high-dose daptomycin in obese patients: a multicentric retrospective study. | |
| dc.title.alternative | Eur J Clin Microbiol Infect Dis | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1007/s10096-025-05065-0 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Médecine humaine et pathologie | en_US |
| dc.identifier.pubmed | 39992533 | en_US |
| bordeaux.journal | European Journal of Clinical Microbiology and Infectious Diseases | en_US |
| bordeaux.hal.laboratories | Biologie des maladies cardiovasculaires (BMC) - UMR 1034 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.institution | CNRS | |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.import.source | pubmed | |
| hal.identifier | hal-04975983 | |
| hal.version | 1 | |
| hal.date.transferred | 2025-03-04T12:54:57Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| workflow.import.source | pubmed | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European%20Journal%20of%20Clinical%20Microbiology%20and%20Infectious%20Diseases&rft.date=2025-02-24&rft.eissn=1435-4373&rft.issn=1435-4373&rft.au=DIAS%20MEIRELES,%20Vasco&AIRAUD,%20Cl%C3%A9mentine&DEMAY,%20Elouan&CAZANAVE,%20Charles&XUEREB,%20Fabien&rft.genre=article |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||